ALA-RDT in GBM: protocol of the phase I/II dose escalation trial of radiodynamic therapy with 5-Aminolevulinic acid in patients with recurrent glioblastoma.

Niklas Benedikt PepperHans Theodor EichMichael MütherMichael OertelStephan RehnDorothee Cäcilia SpilleWalter Stummer

Published in: Radiation oncology (London, England) (2024)

This study was approved by the local ethics committee of the Medical Association of Westphalia-Lippe and the University of Münster on 12.10.2022, the German federal institute for Drugs and medical devices on 13.10.2022 and the federal office for radiation protection on 29.08.2022. This trial was registered on the public European EudraCT database (EudraCT-No.: 2021-004631-92) and is registered under www.cliniclatrials.gov (Identifier: NCT05590689).

Keyphrases

phase iii
study protocol
healthcare
phase ii
clinical trial
open label
randomized controlled trial
public health
photodynamic therapy
mental health
adverse drug
big data
drug administration
bone marrow
mesenchymal stem cells
radiation therapy
smoking cessation